Monoclonal antibodies: A morphing landscape for therapeutics

Drug Development Research

Volumn 67, Issue 10, 2006, Pages 781-789

  Nicolaides, Nicholas C ^a   Sass, Philip M ^a   Grasso, Luigi ^a  

^a Morphotek Inc   (United States)

Author keywords

Antibody therapeutics; Biosimilars; Human MORPHODOMA; Monoclonal antibodies

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; VECTIBIX;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ASTHMA; B CELL LEUKEMIA; B CELL LYMPHOMA; BIOTECHNOLOGY; BREAST CANCER; COLORECTAL CANCER; DNA SHUFFLING; DRUG INDICATION; DRUG MARKETING; GRAFT REJECTION; IMMUNOTHERAPY; ISCHEMIA; MULTIPLE SCLEROSIS; MUSCLE ATROPHY; PHAGE DISPLAY; PSORIASIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

EID: 33846403727     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20149     Document Type: Review

References (23)

1. Amin T, Cahill DP. 2004. Immunogenicity issues with therapeutic proteins. Curr Drug Dis 11:21-24.
2. BCC Research. 2005. Dynamic Antibody Industry Report. Wellesley, MA.
3. Bendig MM. 1988. The production of foreign proteins in mammalian cells. Genet Eng 7:91-127.
4. Borrebaeck C, Ohlin M. 2002. Antibody evolution beyond nature. Nat Biotech 20:1189-1190.
5. Business Insights. 2006. The future of monoclonal antibodies therapeutics: innovation in antibody engineering, key growth strategies and forecasts to 2011. Wellesley, MA.
6. Chirino AJ, Mire-Sluis A. 2004. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotech. 22:1383-1391.
7. Cumbers SJ, Williams GT, Davies SL, Grenfell RL, Takeda S, Batista FD, Sale JL, Neuberger MS. 2002. Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines. Nat Biotech 20:1129-1134.
8. Edfjäll C. 2003. Future regulation of biosimilars. Euro Biotech News Vol. 2: No. 4.
9. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers G, Bajyana Songa E, Bendahman N, Hamers R. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
10. Grasso L, Kline JB, Chao Q, Routhier E, Ebel W, Sass PM, Nicolaides NC. 2004. MOHPHODOMA technology: enhancing therapeutic antibodies and titer yields of mammalian cell lines. Bioprocess Int 2:58-64.
11. Harding FA, Lonberg N. 1995. Class switching in human immunoglobulin transgenic mice. Ann NY Acad Sci 764:536-546.
12. Kline JB, Chao Q, Zhou Y, Routhier E, Ebel W, Feldman S, Sass PM, Grasso L, Nicolaides NC. 2006. Whole-genome evolution technology improving protein and antibody yields in scalable mammalian-cell-based manufacturing. BioProcess Int 4:S42-S47. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
13. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. 1994. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 11:365-372.
14. J, Sai T, Berger M, Chao Q, Davidson D, Deshmukh G, Drozdowski B, Ebel W, Hurley S, Henry M, Jacob S, Kline B,
15. Lazo E, Rotella F, Rudolf K, Routhier E, Sage J, Simon P, Yao J, Zhou Y, Kavuru M, Bonfield T, Thomassen MJ, Sass PM, Nicolaides NC, Grasso L. 2006. Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc Natl Acad Sci USA 103:3557-3562.
16. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. 1991. Bypassing immunization, human antibodies from v-gene libraries displayed on phage. J Mol Biol 222:581-597.
17. Maynard J, Georgiou G. 2000. Antibody engineering. Ann Rev Biomed Eng 2:339-376.
18. Nicolaides NC, Littmann S, Modrich P, Kinzler KW, Vogelstein B. 1998. A naturally occurring hPMS2 mutation can confer a dominant negative imitator phenotype. Mol Cell Biol 18: 1635-1641.
19. Nicolaides NC, Ebel W, Kline JB, Chao Q, Routhier E, Sass PM, Grasso L. 2005. Morphogenics as a tool for drug discovery. Ann NY Acad Sci 1059:1-11.
20. Presta L. 2002. Celebrating diversity and mimicking maturation. Nat Biotech 20:1096-1097.
21. Schellekens H. 2004. How similar do 'biosimilars' need to be? Nat Biotech 22:1357-1359.
22. Watt PM. 2006. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotech 24:177-182.
23. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotech 22:1393-1398.